Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 205 articles:
HTML format



Single Articles


    February 2024
  1. ZHOU I, Plana D, Palmer AC
    Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
    Clin Cancer Res. 2024;30:786-792.
    PubMed     Abstract available


  2. KASI PM, Lee JK, Pasquina LW, Decker B, et al
    Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
    Clin Cancer Res. 2024;30:836-848.
    PubMed     Abstract available


  3. WEI D, Wang L, Zuo X, Maitra A, et al
    A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.
    Clin Cancer Res. 2024;30:655-662.
    PubMed     Abstract available


  4. WANG H, Chen Y, Wang X, Huang B, et al
    Germline mutations of Holliday junction resolvase genes in multiple primary malignancies involving lung cancer lead to PARP inhibitor sensitization.
    Clin Cancer Res. 2024 Feb 13. doi: 10.1158/1078-0432.CCR-22-3300.
    PubMed     Abstract available


  5. VAN DE HAAR J, Mankor JM, Hummelink K, Monkhorst K, et al
    Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer.
    Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-4027.
    PubMed     Abstract available


  6. LAKHANI NJ, Rasco D, Wang H, Men L, et al
    First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
    Clin Cancer Res. 2024;30:506-521.
    PubMed     Abstract available


    January 2024
  7. PARRA ER, Zhang J, Duose DY, Gonzalez-Kozlova E, et al
    Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial.
    Clin Cancer Res. 2024 Jan 26. doi: 10.1158/1078-0432.CCR-23-0251.
    PubMed     Abstract available


  8. GUAN S, Chen X, Wei Y, Wang F, et al
    Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in non-small cell lung cancer patients.
    Clin Cancer Res. 2024 Jan 23. doi: 10.1158/1078-0432.CCR-23-2357.
    PubMed     Abstract available


  9. KESARI S, Wagle N, Carrillo JA, Sharma A, et al
    Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.
    Clin Cancer Res. 2024;30:323-333.
    PubMed     Abstract available


  10. NG J, Cai L, Girard L, Prall OWJ, et al
    Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
    Clin Cancer Res. 2024 Jan 5:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-2360.
    PubMed     Abstract available


  11. NAKAMICHI S, Kubota K, Misumi T, Kondo T, et al
    Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study).
    Clin Cancer Res. 2024 Jan 2. doi: 10.1158/1078-0432.CCR-23-2568.
    PubMed     Abstract available


    December 2023
  12. LOPEZ DE RODAS M, Wang Y, Peng G, Gu J, et al
    Objective analysis and clinical significance of the spatial tumor infiltrating lymphocyte patterns in non-small cell lung cancer (NSCLC).
    Clin Cancer Res. 2023 Dec 21. doi: 10.1158/1078-0432.CCR-23-2457.
    PubMed     Abstract available


  13. PASSIGLIA F, Righi L, Bironzo P, Listi A, et al
    Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial.
    Clin Cancer Res. 2023 Dec 18. doi: 10.1158/1078-0432.CCR-23-2431.
    PubMed     Abstract available


  14. BOUMELHA J, Molina-Arcas M, Downward J
    Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
    Clin Cancer Res. 2023;29:5012-5020.
    PubMed     Abstract available


  15. HUMMELINK K, Tissier R, Bosch LJW, Krijgsman O, et al
    A dysfunctional T cell gene signature for predicting non-response to PD-1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics.
    Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-1061.
    PubMed     Abstract available


  16. ROLFO C, Russo A
    In search of lost biomarker for immunotherapy in small-cell lung cancer.
    Clin Cancer Res. 2023 Dec 12. doi: 10.1158/1078-0432.CCR-23-3087.
    PubMed     Abstract available


  17. BESSEDE A, Peyraud F, Besse B, Cousin S, et al
    TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-2566.
    PubMed     Abstract available


  18. VOKES NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, et al
    ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
    Clin Cancer Res. 2023;29:4958-4972.
    PubMed     Abstract available


    November 2023
  19. MURRAY JC, Sivapalan L, Hummelink K, Balan A, et al
    Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-1469.
    PubMed     Abstract available


    October 2023
  20. HERBST RS, Blanke CD, Sigal EV
    Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of Public-Private Partnerships.
    Clin Cancer Res. 2023 Oct 30. doi: 10.1158/1078-0432.CCR-23-2690.
    PubMed     Abstract available


  21. PAZ-ARES L, Garassino MC, Chen Y, Reinmuth N, et al
    Durvalumab +/- tremelimumab + platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden.
    Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1689.
    PubMed     Abstract available


    September 2023
  22. BESSEDE A, Peyraud F, Le Moulec S, Cousin S, et al
    Upregulation of Indoleamine 2,3-dioxygenase 1 in tumor cells and tertiary lymphoid structures is a hallmark of inflamed non-small cell lung cancer.
    Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-1928.
    PubMed     Abstract available


  23. DIMOU A
    Time to Think About Human Leukocyte Antigen-Based Diagnostics in Lung Cancer?
    Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-2152.
    PubMed     Abstract available


  24. SOLTA A, Boettiger K, Kovacs I, Lang C, et al
    Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair.
    Clin Cancer Res. 2023 Sep 19. doi: 10.1158/1078-0432.CCR-23-1795.
    PubMed     Abstract available


  25. CANTOR DJ, Aggarwal C
    Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.
    Clin Cancer Res. 2023;29:3563-3565.
    PubMed     Abstract available


  26. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2023;29:3573-3578.
    PubMed     Abstract available


  27. ABEL ML, Takahashi N, Peer C, Redon CE, et al
    Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
    Clin Cancer Res. 2023;29:3603-3611.
    PubMed     Abstract available


  28. PELLINI B, Madison RW, Childress M, Miller ST, et al
    Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2023 Sep 13. doi: 10.1158/1078-0432.CCR-23-1578.
    PubMed     Abstract available


    August 2023
  29. ZHOU X, Zhou L, Yao Z, Huang M, et al
    Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients.
    Clin Cancer Res. 2023 Aug 15:CCR-23-0315. doi: 10.1158/1078-0432.CCR-23-0315.
    PubMed     Abstract available


  30. KREBS MG, Popat S
    RETaliation-Tackling Rare Resistance Alterations to Osimertinib.
    Clin Cancer Res. 2023;29:2951-2953.
    PubMed     Abstract available


  31. ROTOW J, Patel JD, Hanley MP, Yu H, et al
    Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
    Clin Cancer Res. 2023;29:2979-2987.
    PubMed     Abstract available


  32. MATHIEU LN, Larkins E, Sinha AK, Mishra-Kalyani PS, et al
    FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC.
    Clin Cancer Res. 2023;29:2973-2978.
    PubMed     Abstract available


  33. VALENCIA K, Montuenga LM, Calvo A
    Estrogen receptor and immune checkpoint inhibitors: new partners in lung cancer?
    Clin Cancer Res. 2023 Aug 7:CCR-23-1736. doi: 10.1158/1078-0432.CCR-23-1736.
    PubMed     Abstract available


    July 2023
  34. JIANG T, Jin Q, Wang J, Wu F, et al
    HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer.
    Clin Cancer Res. 2023 Jul 14:CCR-23-0604. doi: 10.1158/1078-0432.CCR-23-0604.
    PubMed     Abstract available


  35. CORTELLINI A, D'Alessio A, Cleary S, Buti S, et al
    Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
    Clin Cancer Res. 2023;29:2714-2724.
    PubMed     Abstract available


  36. THUMMALAPALLI R, Ricciuti B, Bandlamudi C, Muldoon D, et al
    Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2023 Jul 11:CCR-23-1207. doi: 10.1158/1078-0432.CCR-23-1207.
    PubMed     Abstract available


  37. COLLINS G, Stewart M, McKelvey B, Stires H, et al
    Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies.
    Clin Cancer Res. 2023;29:2371-2374.
    PubMed     Abstract available


    June 2023
  38. CHAKRABORTY S, Coleman C, Manoj P, Demircioglu D, et al
    De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways.
    Clin Cancer Res. 2023 Jun 29:CCR-23-0471. doi: 10.1158/1078-0432.CCR-23-0471.
    PubMed     Abstract available


  39. GRAY JE, Ahn MJ, Oxnard GR, Shepherd FA, et al
    Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
    Clin Cancer Res. 2023 Jun 28:CCR-22-3146. doi: 10.1158/1078-0432.CCR-22-3146.
    PubMed     Abstract available


  40. KABRAJI S, Lin NU
    Keeping it in the family: HER3 as a target in brain metastases.
    Clin Cancer Res. 2023 Jun 12:CCR-23-1107. doi: 10.1158/1078-0432.CCR-23-1107.
    PubMed     Abstract available


  41. RAMKUMAR K, Tanimoto A, Della Corte CM, Stewart CA, et al
    Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer.
    Clin Cancer Res. 2023 Jun 8:CCR-23-0375. doi: 10.1158/1078-0432.CCR-23-0375.
    PubMed     Abstract available


  42. ANOBILE DP, Salaroglio IC, Tabbo F, La Vecchia S, et al
    Autocrine 17-beta-estradiol/estrogen receptor-alpha loop determines the response to immune-checkpoint inhibitors in non-small cell lung cancer.
    Clin Cancer Res. 2023 Jun 7:CCR-22-3949. doi: 10.1158/1078-0432.CCR-22-3949.
    PubMed     Abstract available


  43. PAWELETZ CP, Heavey GA, Kuang Y, Durlacher E, et al
    Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients.
    Clin Cancer Res. 2023 Jun 6:CCR-23-0795. doi: 10.1158/1078-0432.CCR-23-0795.
    PubMed     Abstract available


    May 2023
  44. LIM SM, Fujino T, Kim C, Lee G, et al
    BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2023 May 30:CCR-22-3901. doi: 10.1158/1078-0432.CCR-22-3901.
    PubMed     Abstract available


  45. EISNER JR, Mayhew GM, Davison JM, Beebe KD, et al
    Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer - The Piedmont Study.
    Clin Cancer Res. 2023 May 26:CCR-22-2558. doi: 10.1158/1078-0432.CCR-22-2558.
    PubMed     Abstract available


  46. GADGEEL SM, Miao J, Riess JW, Moon J, et al
    Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042).
    Clin Cancer Res. 2023 May 26:CCR-22-3947. doi: 10.1158/1078-0432.CCR-22-3947.
    PubMed     Abstract available


  47. BHATT A, Schabath MB, Hoogland AI, Jim HSL, et al
    Patient-Reported Outcomes as Inter-Radiographic Predictors of Response in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2023 May 26:CCR-23-0396. doi: 10.1158/1078-0432.CCR-23-0396.
    PubMed     Abstract available


  48. CHOUDHURY NJ, Lavery JA, Brown S, de Bruijn I, et al
    The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer.
    Clin Cancer Res. 2023 May 24:CCR-23-0580. doi: 10.1158/1078-0432.CCR-23-0580.
    PubMed     Abstract available


  49. LIAM CK, Ahmad AR, Hsia TC, Zhou J, et al
    Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.
    Clin Cancer Res. 2023;29:1879-1886.
    PubMed     Abstract available


    April 2023
  50. RICCIUTI B, Elkrief A, Alessi J, Wang X, et al
    Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer.
    Clin Cancer Res. 2023 Apr 25:CCR-22-3413. doi: 10.1158/1078-0432.CCR-22-3413.
    PubMed     Abstract available


  51. PELLINI B, Chaudhuri AA
    ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?
    Clin Cancer Res. 2023 Apr 25:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-0420.
    PubMed     Abstract available


  52. BLAQUIER JB, Ortiz-Cuaran S, Ricciuti B, Mezquita L, et al
    Tackling osimertinib resistance in EGFR mutant non-small cell lung cancer.
    Clin Cancer Res. 2023 Apr 24:CCR-22-1912. doi: 10.1158/1078-0432.CCR-22-1912.
    PubMed     Abstract available


  53. SIVAPALAN L, Iams WT, Belcaid Z, Scott SC, et al
    Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer.
    Clin Cancer Res. 2023 Apr 18:OF1-OF14. doi: 10.1158/1078-0432.CCR-22-2242.
    PubMed     Abstract available


  54. JACOBSEN SKANDERUP A, Ang SF, Tan DSW
    Liquid Biopsies for Cancer Genotyping: Coming of Age?
    Clin Cancer Res. 2023;29:1381-1383.
    PubMed     Abstract available


  55. ELKRIEF A, Makhnin A, Moses KA, Ahn LS, et al
    Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
    Clin Cancer Res. 2023;29:1423-1428.
    PubMed     Abstract available


  56. TOMASICH E, Steindl A, Paiato C, Hatziioannou T, et al
    Frequent overexpression of HER3 in brain metastases from breast and lung cancer.
    Clin Cancer Res. 2023 Apr 10:CCR-23-0020. doi: 10.1158/1078-0432.CCR-23-0020.
    PubMed     Abstract available


  57. CHON K, Larkins E, Chatterjee S, Mishra-Kalyani PS, et al
    FDA Approval Summary: Amivantamab for the Treatment of patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Clin Cancer Res. 2023 Apr 6:CCR-22-3713. doi: 10.1158/1078-0432.CCR-22-3713.
    PubMed     Abstract available


  58. TUCKER ER, Jimenez I, Chen L, Bellini A, et al
    Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
    Clin Cancer Res. 2023;29:1317-1331.
    PubMed     Abstract available


  59. PATEL SA, Nilsson MB, Yang Y, Le X, et al
    IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.
    Clin Cancer Res. 2023;29:1292-1304.
    PubMed     Abstract available


    March 2023
  60. XIA L, Yang Y, Chen W, Liu L, et al
    Perioperative ctDNA-Based MRD Detection in NSCLC-Response.
    Clin Cancer Res. 2023;29:1156.
    PubMed    


  61. YU M, Ju L, Cao X
    Perioperative ctDNA-Based MRD Detection in NSCLC-Letter.
    Clin Cancer Res. 2023;29:1155.
    PubMed    


  62. BRUNO R, Marchand M, Yoshida K, Chan P, et al
    Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
    Clin Cancer Res. 2023;29:1047-1055.
    PubMed     Abstract available


  63. GRANT MJ, Aredo JV, Starrett JH, Stockhammer P, et al
    Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations.
    Clin Cancer Res. 2023 Mar 13:CCR-22-3497. doi: 10.1158/1078-0432.CCR-22-3497.
    PubMed     Abstract available


  64. GURSKA LM, Okabe R, Schurer A, Tong MM, et al
    Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
    Clin Cancer Res. 2023;29:943-956.
    PubMed     Abstract available


    February 2023
  65. WILDSMITH S, Li W, Wu S, Stewart R, et al
    Tumor Mutational Burden as a Predictor of Survival With Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2023 Feb 20:CCR-22-2765. doi: 10.1158/1078-0432.CCR-22-2765.
    PubMed     Abstract available


  66. ROSNER S, Reuss JE, Zahurak M, Zhang J, et al
    Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2023;29:705-710.
    PubMed     Abstract available


  67. WIJETUNGA NA, Goglia AG, Weinhold N, Berger MF, et al
    Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases.
    Clin Cancer Res. 2023;29:775-783.
    PubMed     Abstract available


  68. OWEN DH, Benner B, Wei L, Sukrithan V, et al
    A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
    Clin Cancer Res. 2023;29:731-741.
    PubMed     Abstract available


  69. ROSNER S, Reuss JE, Zahurak M, Zhang J, et al
    Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2023 Feb 15:OF1-OF6. doi: 10.1158/1078-0432.CCR-22-2994.
    PubMed     Abstract available


  70. LEE HS, Jang HJ, Ramineni M, Wang DY, et al
    A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
    Clin Cancer Res. 2023;29:548-559.
    PubMed     Abstract available


  71. AUGUSTIN RC, Bao R, Luke JJ
    Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones.
    Clin Cancer Res. 2023;29:505-507.
    PubMed     Abstract available


  72. WANG J, Guo W, Wang X, Tang X, et al
    Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma.
    Clin Cancer Res. 2023;29:659-666.
    PubMed     Abstract available


    January 2023
  73. ZHANG Y, Tacheva-Grigorova SK, Sutton J, Melton Z, et al
    Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer.
    Clin Cancer Res. 2023 Jan 23:OF1-OF15. doi: 10.1158/1078-0432.CCR-22-2293.
    PubMed     Abstract available


  74. JONES R, Plummer R, Moreno V, Carter L, et al
    A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
    Clin Cancer Res. 2023;29:331-340.
    PubMed     Abstract available


  75. OH SY, Lee YW, Lee EJ, Kim JH, et al
    Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC.
    Clin Cancer Res. 2023;29:221-232.
    PubMed     Abstract available


  76. WAINBERG ZA, Singh AS, Konecny GE, McCann KE, et al
    Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
    Clin Cancer Res. 2023;29:40-49.
    PubMed     Abstract available


    December 2022
  77. PALANKI R, Swingle KL, Mitchell MJ
    A (Controlled) Spill of IL2 for Localized Treatment of Mesothelioma.
    Clin Cancer Res. 2022;28:5010-5012.
    PubMed     Abstract available


  78. NASH AM, Aghlara-Fotovat S, Castillio B, Hernandez A, et al
    Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors.
    Clin Cancer Res. 2022;28:5121-5135.
    PubMed     Abstract available


    November 2022
  79. ANAGNOSTOU V, Luke JJ
    Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade.
    Clin Cancer Res. 2022;28:4835-4837.
    PubMed     Abstract available


  80. LIM EA, Bendell JC, Falchook GS, Bauer TM, et al
    Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
    Clin Cancer Res. 2022;28:4871-4884.
    PubMed     Abstract available


  81. HUMMELINK K, van der Noort V, Muller M, Schouten RD, et al
    PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.
    Clin Cancer Res. 2022;28:4893-4906.
    PubMed     Abstract available


  82. POULIKAKOS PI, Sullivan RJ, Yaeger R
    Molecular Pathways and Mechanisms of BRAF in Cancer Therapy.
    Clin Cancer Res. 2022;28:4618-4628.
    PubMed     Abstract available


    October 2022
  83. BRAMAN N, Prasanna P, Bera K, Alilou M, et al
    Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers.
    Clin Cancer Res. 2022;28:4410-4424.
    PubMed     Abstract available


  84. SUGIMOTO A, Matsumoto S, Udagawa H, Itotani R, et al
    A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid).
    Clin Cancer Res. 2022 Oct 6. pii: 709652. doi: 10.1158/1078-0432.CCR-22-1749.
    PubMed     Abstract available


  85. JUNG HA, Lim J, Choi YL, Lee SH, et al
    Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.
    Clin Cancer Res. 2022;28:4312-4321.
    PubMed     Abstract available


    September 2022
  86. ROCHIGNEUX P, Lisberg A, Garcia A, Granjeaud S, et al
    Mass cytometry reveals classical monocytes, NK cells and ICOS+ CD4+ T cells associated with pembrolizumab efficacy in lung cancer patients.
    Clin Cancer Res. 2022 Sep 27. pii: 709487. doi: 10.1158/1078-0432.CCR-22-1386.
    PubMed     Abstract available


  87. ROTOLO R, Leuci V, Donini C, Galvagno F, et al
    Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells.
    Clin Cancer Res. 2022 Sep 27. pii: 709485. doi: 10.1158/1078-0432.CCR-22-0761.
    PubMed     Abstract available


  88. DUKE ES, Stapleford L, Drezner N, Amatya AK, et al
    FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
    Clin Cancer Res. 2022 Sep 16. pii: 709236. doi: 10.1158/1078-0432.CCR-22-2072.
    PubMed     Abstract available


  89. GUIDRY K, Vasudevaraja V, Labbe K, Mohamed H, et al
    DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome.
    Clin Cancer Res. 2022;28:3824-3835.
    PubMed     Abstract available


  90. KENNEDY GT, Holt DE, Azari FS, Bernstein E, et al
    A Cathepsin-Targeted Quenched Activity-Based Probe Facilitates Enhanced Detection of Human Tumors during Resection.
    Clin Cancer Res. 2022;28:3729-3741.
    PubMed     Abstract available


  91. MACK PC, Miao J, Redman MW, Moon J, et al
    Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).
    Clin Cancer Res. 2022;28:3752-3760.
    PubMed     Abstract available


  92. YAP TA, Gainor JF, Callahan MK, Falchook GS, et al
    First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
    Clin Cancer Res. 2022;28:3695-3708.
    PubMed     Abstract available


    August 2022
  93. MAHADEVAN NR, Sholl LM
    To Rb or Not to Rb: Uncovering Unique Subsets of Small Cell Lung Carcinoma.
    Clin Cancer Res. 2022 Aug 31. pii: 708945. doi: 10.1158/1078-0432.CCR-22-2187.
    PubMed     Abstract available


  94. TANIGUCHI Y, Shimokawa T, Takiguchi Y, Misumi T, et al
    A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naive non-small-cell lung cancer: TORG1630.
    Clin Cancer Res. 2022 Aug 18. pii: 708059. doi: 10.1158/1078-0432.CCR-22-1687.
    PubMed     Abstract available


  95. OZCAN G, Singh M, Vredenburgh JJ
    Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments.
    Clin Cancer Res. 2022 Aug 16. pii: 707826. doi: 10.1158/1078-0432.CCR-22-1585.
    PubMed     Abstract available


  96. KIM TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, et al
    First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2022;28:3452-3463.
    PubMed     Abstract available


  97. HIATT JB, Sandborg H, Garrison SM, Arnold HU, et al
    Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T cell killing.
    Clin Cancer Res. 2022 Aug 3. pii: 707373. doi: 10.1158/1078-0432.CCR-22-1128.
    PubMed     Abstract available


  98. WEI S, Gao X, Tang M, Li J, et al
    Perioperative ctDNA-Based MRD Detection in NSCLC- Letter.
    Clin Cancer Res. 2022;28:3400.
    PubMed    


  99. XIA L, Chen W, Liu L
    Perioperative ctDNA-Based MRD Detection in NSCLC-Response.
    Clin Cancer Res. 2022;28:3401.
    PubMed    


    July 2022
  100. HUNIHAN L, Zhao D, Lazowski H, Li M, et al
    RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.
    Clin Cancer Res. 2022;28:3091-3103.
    PubMed     Abstract available


  101. BARLESI F, Tomasini P, Karimi M, Michiels S, et al
    Comprehensive genome profiling in patients with metastatic non-small cell lung cancer: the precision medicine phase 2 randomized SAFIR02-Lung trial.
    Clin Cancer Res. 2022 Jul 8. pii: 706925. doi: 10.1158/1078-0432.CCR-22-0371.
    PubMed     Abstract available


  102. FEBRES ALDANA CA, Chang JC, Ptashkin R, Wang Y, et al
    Rb tumor suppressor in small cell lung cancer: Combined genomic and immunohistochemical analysis with a description of a distinct Rb-proficient subset.
    Clin Cancer Res. 2022 Jul 6. pii: 706889. doi: 10.1158/1078-0432.CCR-22-1115.
    PubMed     Abstract available


    June 2022
  103. SCHOENFELD AJ, Rizvi HA, Memon D, Shaverdian N, et al
    Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer.
    Clin Cancer Res. 2022 Jun 29. pii: 705289. doi: 10.1158/1078-0432.CCR-22-0657.
    PubMed     Abstract available


  104. AKAMATSU H, Teraoka S, Takamori S, Miura S, et al
    Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L).
    Clin Cancer Res. 2022 Jun 28:OF1-OF7. doi: 10.1158/1078-0432.CCR-22-0602.
    PubMed     Abstract available


  105. YANG JC, Ohe Y, Chiu CH, Ou X, et al
    Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B).
    Clin Cancer Res. 2022 Jun 23:OF1-OF10. doi: 10.1158/1078-0432.CCR-21-4329.
    PubMed     Abstract available


  106. GUAN S, Chen X, Chen Y, Xie W, et al
    FOXM1 variant contributes to gefitinib resistance via activating wnt/beta-catenin signal pathway in non-small cell lung cancer patients.
    Clin Cancer Res. 2022 Jun 13. pii: 704872. doi: 10.1158/1078-0432.CCR-22-0791.
    PubMed     Abstract available


  107. MURCIANO-GOROFF YR, Harada G, Drilon A
    An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers.
    Clin Cancer Res. 2022;28:2477-2479.
    PubMed     Abstract available


  108. TAKEMOTO A, Takagi S, Ukaji T, Gyobu N, et al
    Targeting Podoplanin for the Treatment of Osteosarcoma.
    Clin Cancer Res. 2022;28:2633-2645.
    PubMed     Abstract available


  109. ROCHA P, Zhang J, Laza-Briviesca R, Cruz-Bermudez A, et al
    Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
    Clin Cancer Res. 2022;28:2461-2473.
    PubMed     Abstract available


  110. TSENG D, Gainor JF
    Searching for Synergy: Chemotherapy and Checkpoint Inhibitors.
    Clin Cancer Res. 2022;28:2206-2208.
    PubMed     Abstract available


  111. PATIL T, Bunn PA
    Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?
    Clin Cancer Res. 2022;28:2204-2205.
    PubMed     Abstract available


  112. CHOUDHURY AD, Higano CS, de Bono JS, Cook N, et al
    A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kbeta/delta, in Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2022;28:2257-2269.
    PubMed     Abstract available


  113. AKINBORO O, Larkins E, Pai-Scherf LH, Mathieu LN, et al
    FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
    Clin Cancer Res. 2022;28:2221-2228.
    PubMed     Abstract available


  114. JUNG HA, Park S, Choi YL, Lee SH, et al
    Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study.
    Clin Cancer Res. 2022;28:2321-2328.
    PubMed     Abstract available


    May 2022
  115. AKAMATSU H, Teraoka S, Takamori S, Miura S, et al
    Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L).
    Clin Cancer Res. 2022 May 26. pii: 699251. doi: 10.1158/1078-0432.CCR-22-0602.
    PubMed     Abstract available


  116. YANG JC, Ohe Y, Chiu CH, Ou X, et al
    Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B).
    Clin Cancer Res. 2022 May 26. pii: 699247. doi: 10.1158/1078-0432.CCR-21-4329.
    PubMed     Abstract available


  117. KOMMALAPATI A, Mansfield AS
    Trials, tribunals, and opportunities for lung cancer KRASG12C brain metastases.
    Clin Cancer Res. 2022 May 24. pii: 699172. doi: 10.1158/1078-0432.CCR-22-1137.
    PubMed     Abstract available


  118. FRIZZIERO M, Kilgour E, Simpson KL, Rothwell DG, et al
    Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.
    Clin Cancer Res. 2022;28:1999-2019.
    PubMed     Abstract available


  119. MOORTHI S, Berger AH
    All about that Ras: Novel fusion drives Ras pathway activation in lung cancer.
    Clin Cancer Res. 2022 May 5. pii: 696314. doi: 10.1158/1078-0432.CCR-22-0736.
    PubMed     Abstract available


  120. TON TGN, Pal N, Trinh H, Mahrus S, et al
    Replication of overall survival, progression-free survival, and overall response in chemotherapy arms of non-small cell lung cancer trials using real-world data.
    Clin Cancer Res. 2022 May 5. pii: 696304. doi: 10.1158/1078-0432.CCR-22-0471.
    PubMed     Abstract available


    April 2022
  121. SONG L, Xiong H, Li J, Liao W, et al
    Correction: Sphingosine Kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NFkappaB Pathway in Human Non-small Cell Lung Cancer.
    Clin Cancer Res. 2022;28:1740.
    PubMed    


  122. NAKAJIMA EC, Drezner N, Li X, Mishra-Kalyani PS, et al
    FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
    Clin Cancer Res. 2022;28:1482-1486.
    PubMed     Abstract available


  123. SABARI JK, Velcheti V, Shimizu K, Strickland MR, et al
    Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2022 Apr 11. pii: 694212. doi: 10.1158/1078-0432.CCR-22-0383.
    PubMed     Abstract available


  124. DEMETRI GD, De Braud F, Drilon A, Siena S, et al
    Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2022;28:1302-1312.
    PubMed     Abstract available


    March 2022
  125. ROSNER S, Spira AI
    Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study.
    Clin Cancer Res. 2022;28:1055-1057.
    PubMed     Abstract available


  126. LE X, Sakai H, Felip E, Veillon R, et al
    Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
    Clin Cancer Res. 2022;28:1117-1126.
    PubMed     Abstract available


  127. DZIADZIUSZKO R, Peters S, Mok T, Camidge DR, et al
    Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
    Clin Cancer Res. 2022 Mar 11. pii: 681795. doi: 10.1158/1078-0432.CCR-21-2840.
    PubMed     Abstract available


  128. CHIAPPORI AA, Creelan B, Tanvetyanon T, Gray JE, et al
    Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2022 Mar 7. pii: 682078. doi: 10.1158/1078-0432.CCR-21-2742.
    PubMed     Abstract available


  129. HAYASHI H, Sugawara S, Fukuda Y, Fujimoto D, et al
    A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
    Clin Cancer Res. 2022;28:893-902.
    PubMed     Abstract available


    February 2022
  130. LEE JK, Hazar-Rethinam M, Decker B, Gjoerup O, et al
    The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.
    Clin Cancer Res. 2022;28:728-737.
    PubMed     Abstract available


  131. MAJEED S, Aparnathi MK, Nixon KCJ, Venkatasubramanian V, et al
    Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small cell lung cancer.
    Clin Cancer Res. 2022 Feb 14. pii: 1078-0432.CCR-21-0344.
    PubMed     Abstract available


  132. MAJEED S, Aparnathi MK, Nixon KCJ, Venkatasubramanian V, et al
    Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small cell lung cancer.
    Clin Cancer Res. 2022 Feb 11. pii: 681703. doi: 10.1158/1078-0432.CCR-21-0344.
    PubMed     Abstract available


  133. NAKAJIMA EC, Vellanki PJ, Larkins E, Chatterjee S, et al
    FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
    Clin Cancer Res. 2022;28:446-451.
    PubMed     Abstract available


    January 2022
  134. CHOW LQM, Barlesi F, Bertino EM, van den Bent MJ, et al
    ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-1838.
    PubMed     Abstract available


  135. RICCIUTI B, Son J, Okoro JJ, Mira A, et al
    Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-2719.
    PubMed     Abstract available


  136. TULLY KM, Tendler S, Carter LM, Sharma SK, et al
    Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer exhibits antitumor efficacy with low toxicity.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-1533.
    PubMed     Abstract available


  137. SUZUKI S, Yonesaka K, Teramura T, Takehara T, et al
    Correction: KRAS Inhibitor Resistance in MET-Amplified KRAS (G12C) Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.
    Clin Cancer Res. 2022;28:428.
    PubMed    


  138. MATHIEU LN, Larkins E, Akinboro O, Roy P, et al
    FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
    Clin Cancer Res. 2022;28:249-254.
    PubMed     Abstract available


  139. MAJEM M, Goldman JW, John T, Grohe C, et al
    Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer who underwent Adjuvant Osimertinib in the phase III ADAURA trial.
    Clin Cancer Res. 2022 Jan 10. pii: 1078-0432.CCR-21-3530.
    PubMed     Abstract available


  140. GAO Y, Paivinen P, Tripathi S, Domenech-Moreno E, et al
    Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma.
    Clin Cancer Res. 2022;28:227-237.
    PubMed     Abstract available


  141. LEE JC, Green MD, Huppert LA, Chow C, et al
    The Liver-Immunity Nexus and Cancer Immunotherapy.
    Clin Cancer Res. 2022;28:5-12.
    PubMed     Abstract available


    December 2021
  142. YONESAKA K, Tanizaki J, Maenishi O, Haratani K, et al
    HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-3359.
    PubMed     Abstract available


  143. JIN Y, Chen Y, Tang H, Hubert SM, et al
    Activation of PI3K/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer.
    Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-1943.
    PubMed     Abstract available


  144. DI NOIA V, Pimpinelli F, Renna D, Barberi V, et al
    Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
    Clin Cancer Res. 2021;27:6815-6823.
    PubMed     Abstract available


  145. HANNAN R, Mohamad O, Diaz de Leon A, Manna S, et al
    Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.
    Clin Cancer Res. 2021;27:6716-6725.
    PubMed     Abstract available


  146. LEE CJ, Schoffski P, Modave E, van Wezel T, et al
    Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib.
    Clin Cancer Res. 2021;27:6737-6748.
    PubMed     Abstract available


    November 2021
  147. XIA L, Mei J, Kang R, Deng S, et al
    Perioperative ctDNA-based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-3044.
    PubMed     Abstract available


  148. SONG Z, Lv D, Chen SQ, Huang J, et al
    Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
    Clin Cancer Res. 2021 Nov 9. pii: 1078-0432.CCR-21-2936.
    PubMed     Abstract available


  149. ZHOU Q, Wu L, Hu P, An T, et al
    A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study.
    Clin Cancer Res. 2021 Nov 5. pii: 1078-0432.CCR-21-2595.
    PubMed     Abstract available


  150. BISWAS T, Dowlati A, Kunos CA, Pink JJ, et al
    Adding Base Excision Repair Inhibitor TRC102 to standard Pemetrexed-Platinum-Radiation in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of a phase I trial.
    Clin Cancer Res. 2021 Nov 5. pii: 1078-0432.CCR-21-2025.
    PubMed     Abstract available


  151. CASARRUBIOS M, Cruz-Bermudez A, Nadal E, Insa A, et al
    Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
    Clin Cancer Res. 2021;27:5878-5890.
    PubMed     Abstract available


  152. CHUA KP, Teng YHF, Tan AC, Takano A, et al
    Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities.
    Clin Cancer Res. 2021;27:5939-5950.
    PubMed     Abstract available


    October 2021
  153. MEHTA S, Fiorelli R, Bao X, Pennington-Krygier C, et al
    A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma.
    Clin Cancer Res. 2021 Oct 26. pii: 1078-0432.CCR-21-1096.
    PubMed     Abstract available


  154. GAVRIELATOU N, Liu Y, Vathiotis I, Zugazagoitia J, et al
    Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Oct 22. pii: 1078-0432.CCR-21-2649.
    PubMed     Abstract available


    September 2021
  155. KAWAZOE A, Itahashi K, Yamamoto N, Kotani D, et al
    TAS-116 plus nivolumab in patients with colorectal cancer and other solid tumors: an, open-label, dose-finding, and expansion phase Ib trial (EPOC1704).
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1929.
    PubMed     Abstract available


  156. PORCIUNCULA A, Morgado M, Gupta R, Syrigos K, et al
    Spatial mapping and immunomodulatory role of the OX40/OX40L pathway in human non-small cell lung cancer.
    Clin Cancer Res. 2021 Sep 13. pii: 1078-0432.CCR-21-0987.
    PubMed     Abstract available


    August 2021
  157. SHI J, Wang Z, Zhang J, Xu Y, et al
    Genomic landscape and tumor mutational burden determination of circulating tumor DNA in over 5,000 Chinese lung cancer patients.
    Clin Cancer Res. 2021 Aug 26. pii: 1078-0432.CCR-21-1537.
    PubMed     Abstract available


  158. CAMIDGE DR, Morgensztern D, Heist RS, Barve M, et al
    Phase 1 Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma.
    Clin Cancer Res. 2021 Aug 23. pii: 1078-0432.CCR-21-0765.
    PubMed     Abstract available


  159. MAITLAND ML, Sachdev JC, Sharma MR, Moreno V, et al
    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Clin Cancer Res. 2021;27:4511-4520.
    PubMed     Abstract available


  160. SUZUKI S, Yonesaka K, Teramura T, Takehara T, et al
    KRAS inhibitor-resistance in MET-amplified KRAS (G12C) non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms.
    Clin Cancer Res. 2021 Aug 7. pii: 1078-0432.CCR-21-0856.
    PubMed     Abstract available


  161. SUBBIAH V, Gainor JF, Oxnard GR, Tan DSW, et al
    Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.
    Clin Cancer Res. 2021;27:4160-4167.
    PubMed     Abstract available


  162. KIM SY, Kim SM, Lim S, Lee JY, et al
    Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
    Clin Cancer Res. 2021;27:4397-4409.
    PubMed     Abstract available


  163. CONFORTI F, Pala L, Pagan E, Bagnardi V, et al
    Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion.
    Clin Cancer Res. 2021;27:4311-4324.
    PubMed     Abstract available


    July 2021
  164. NAKAGAWA K, Nadal E, Garon EB, Nishio M, et al
    RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-small Cell Lung Cancer.
    Clin Cancer Res. 2021 Jul 22. pii: 1078-0432.CCR-21-0273.
    PubMed     Abstract available


  165. KOCH AL, Vellanki PJ, Drezner N, Li X, et al
    FDA Approval Summary: Osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative Project Orbis review.
    Clin Cancer Res. 2021 Jul 22. pii: 1078-0432.CCR-21-1034.
    PubMed     Abstract available


  166. CHANG JC, Offin M, Falcon C, Brown D, et al
    Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.
    Clin Cancer Res. 2021;27:4066-4076.
    PubMed     Abstract available


  167. LUO J, Martucci VL, Quandt Z, Groha S, et al
    Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer.
    Clin Cancer Res. 2021 Jul 8. pii: 1078-0432.CCR-21-0921.
    PubMed     Abstract available


  168. FOSTER JH, Voss SD, Hall DC, Minard CG, et al
    Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912).
    Clin Cancer Res. 2021;27:3543-3548.
    PubMed     Abstract available


    June 2021
  169. WEISS SA, Djureinovic D, Jessel S, Krykbaeva I, et al
    A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1.
    Clin Cancer Res. 2021 Jun 17. pii: 1078-0432.CCR-21-0903.
    PubMed     Abstract available


  170. RAGHAV K, Hwang H, Jacome AA, Bhang E, et al
    Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary.
    Clin Cancer Res. 2021;27:3414-3421.
    PubMed     Abstract available


  171. GARON EB, Spira AI, Johnson M, Bazhenova L, et al
    A phase 1b open-label, multicenter study of inhaled DV281, a TLR9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0263.
    PubMed     Abstract available


  172. LEWIS CD, Singh AK, Hsu FF, Thotala D, et al
    Targeting a Radiosensitizing Antibody-Drug Conjugate to a Radiation-Inducible Antigen.
    Clin Cancer Res. 2021;27:3224-3233.
    PubMed     Abstract available


  173. COMPTE M, Harwood SL, Erce-Llamazares A, Tapia-Galisteo A, et al
    An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
    Clin Cancer Res. 2021;27:3167-3177.
    PubMed     Abstract available


    May 2021
  174. KIM J, Bradford D, Larkins E, Pai-Scherf LH, et al
    FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-0967.
    PubMed     Abstract available


  175. CORTOT AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, et al
    First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study.
    Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-20-4604.
    PubMed     Abstract available


  176. CHOUDHURY NJ, Schoenfeld AJ, Flynn J, Falcon CJ, et al
    Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
    Clin Cancer Res. 2021;27:2920-2927.
    PubMed     Abstract available


  177. BYERS LA, Bentsion D, Gans S, Penkov K, et al
    Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
    Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-20-4259.
    PubMed     Abstract available


  178. JONES GD, Caso R, Tan KS, Mastrogiacomo B, et al
    KRAS (G12C) Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.
    Clin Cancer Res. 2021;27:2604-2612.
    PubMed     Abstract available


    April 2021
  179. CHEN K, Nie Y, Park S, Zhang K, et al
    Development and Validation of Machine Learning-based Model for the Prediction of Malignancy in Multiple Pulmonary Nodules: Analysis from Multicentric Cohorts.
    Clin Cancer Res. 2021;27:2255-2265.
    PubMed     Abstract available


  180. OEHL K, Vrugt B, Wagner U, Kirschner MB, et al
    Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma.
    Clin Cancer Res. 2021;27:2277-2291.
    PubMed     Abstract available


  181. DREYFUSS AD, Goia D, Shoniyozov K, Shewale SV, et al
    A Novel Mouse Model of Radiation-Induced Cardiac Injury Reveals Biological and Radiological Biomarkers of Cardiac Dysfunction with Potential Clinical Relevance.
    Clin Cancer Res. 2021;27:2266-2276.
    PubMed     Abstract available


  182. SHAFIQUE M, Fisher TL, Evans EE, Leonard JE, et al
    A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Apr 5. pii: 1078-0432.CCR-20-4792.
    PubMed     Abstract available


    March 2021
  183. BERTINO EM, Gentzler RD, Clifford S, Kolesar J, et al
    Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).
    Clin Cancer Res. 2021;27:1604-1611.
    PubMed     Abstract available


  184. SI H, Kuziora M, Quinn KJ, Helman E, et al
    A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
    Clin Cancer Res. 2021;27:1631-1640.
    PubMed     Abstract available


  185. SITTHIDEATPHAIBOON P, Galan-Cobo A, Negrao MV, Qu X, et al
    STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition.
    Clin Cancer Res. 2021;27:1720-1733.
    PubMed     Abstract available


  186. AGGARWAL C, Thompson JC, Carpenter EL
    Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response.
    Clin Cancer Res. 2021;27:1581.
    PubMed    


  187. XUE Z, Guo X, Wen J, Cai W, et al
    Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter.
    Clin Cancer Res. 2021;27:1580.
    PubMed    


  188. ESTRADA-BERNAL A, Le AT, Doak AE, Tirunagaru VG, et al
    Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
    Clin Cancer Res. 2021;27:1463-1475.
    PubMed     Abstract available


  189. HACKENG WM, Dreijerink KMA, de Leng WWJ, Morsink FHM, et al
    Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool.
    Clin Cancer Res. 2021;27:1341-1350.
    PubMed     Abstract available


  190. ZHOU C, Wang Y, Zhao J, Chen G, et al
    Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.
    Clin Cancer Res. 2021;27:1296-1304.
    PubMed     Abstract available


  191. TANIMOTO A, Matsumoto S, Takeuchi S, Arai S, et al
    Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.
    Clin Cancer Res. 2021;27:1410-1420.
    PubMed     Abstract available


    February 2021
  192. GARON EB
    Osimertinib plus Ramucirumab: The Best of Both Worlds?
    Clin Cancer Res. 2021;27:905-907.
    PubMed     Abstract available


  193. SKOULIDIS F
    Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes.
    Clin Cancer Res. 2021;27:913-915.
    PubMed     Abstract available


  194. HELLMANN MD, Janne PA, Opyrchal M, Hafez N, et al
    Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
    Clin Cancer Res. 2021;27:1019-1028.
    PubMed     Abstract available


  195. TAN Y, Sementino E, Cheung M, Peri S, et al
    Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma.
    Clin Cancer Res. 2021;27:1200-1213.
    PubMed     Abstract available


  196. DAEMEN A, Cooper JE, Myrta S, Wongchenko MJ, et al
    Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
    Clin Cancer Res. 2021;27:1162-1173.
    PubMed     Abstract available


  197. AI X, Cui J, Zhang J, Chen R, et al
    Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641).
    Clin Cancer Res. 2021;27:704-712.
    PubMed     Abstract available


  198. GUO R, Offin M, Brannon AR, Chang J, et al
    MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
    Clin Cancer Res. 2021;27:799-806.
    PubMed     Abstract available


    January 2021
  199. RAHMA OE, Reuss JE, Giobbie-Hurder A, Shoja E Razavi G, et al
    Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2021;27:485-491.
    PubMed     Abstract available


  200. GEIGER T, Beck L, Harel M, Yu S, et al
    Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ-Specificity and Treatment Resistance.
    Clin Cancer Res. 2021 Jan 14. pii: 1078-0432.CCR-20-3752.
    PubMed     Abstract available


  201. DEUTSCH E, Chargari C, Weichselbaum RR, Levy A, et al
    Drug-Radiotherapy Combination Trial Developments-Response.
    Clin Cancer Res. 2021;27:356.
    PubMed    


  202. EVANS JR, Cuneo KC, Lawrence TS
    Drug-Radiotherapy Combination Trial Developments-Letter.
    Clin Cancer Res. 2021;27:355.
    PubMed    


  203. COLCLOUGH N, Chen K, Johnstrom P, Strittmatter N, et al
    Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs.
    Clin Cancer Res. 2021;27:189-201.
    PubMed     Abstract available


    November 2020
  204. BRADFORD D, Larkins E, Mushti SL, Rodriguez L, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.
    Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-3558.
    PubMed     Abstract available


    April 2020
  205. EGUREN-SANTAMARIA I, Sanmamed MF, Goldberg SB, Kluger HM, et al
    PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice.
    Clin Cancer Res. 2020 Apr 30. pii: 1078-0432.CCR-20-0798.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.